文献速递甲状腺疾病垂体与肾上腺疾病糖尿病

免疫检查点抑制剂相关内分泌功能障碍患者的诊疗方法

Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

免疫检查点抑制剂(ICI)已获批用于至少19种癌症,内分泌毒性在ICI受者中发生率高达25%至50%,轻重不一,可从亚临床甲状腺功能减退到肾上腺危象、甲状腺功能障碍或糖尿病酮症酸中毒等致命情况。本文通过ICI所致甲状腺功能障碍、垂体炎和胰岛素依赖型糖尿病的临床病例,讨论其筛查、诊断与管理。

要点

  • ICI受者内分泌毒性发生率高达25%至50%,取决于所用治疗方案。
  • 内分泌毒性谱从轻度无症状亚临床甲状腺功能减退到致命性肾上腺危象、甲状腺功能障碍或糖尿病酮症酸中毒。
  • 及时识别与治疗至关重要,本文以病例形式讨论筛查、诊断与管理。

核心结论

  • ICI相关内分泌毒性发生率高、谱广,可从轻度亚临床甲状腺功能减退至致命性肾上腺危象、甲状腺功能障碍或糖尿病酮症酸中毒,及时识别与治疗至关重要。

研究设计与样本

  • 本文为病例导向的临床综述,呈现ICI所致甲状腺功能障碍、垂体炎和胰岛素依赖型糖尿病的临床病例,并据此讨论筛查、诊断与管理。

主要发现

  • 内分泌毒性在ICI受者中发生率高达25%至50%,取决于所用治疗方案。
  • 内分泌毒性轻重不一,包括轻度无症状的亚临床甲状腺功能减退,以及严重的致命性肾上腺危象、甲状腺功能障碍或糖尿病酮症酸中毒。
  • 本文呈现的病例涵盖ICI所致甲状腺功能障碍、垂体炎和胰岛素依赖型糖尿病。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICI) are cancer therapies that are approved for use in at least 19 different cancers. They function by stimulating immune cell responses against cancer, and their toxicities comprise a host of autoinflammatory syndromes that may impact any organ system. Endocrine toxicities occur in as high as 25% to 50% of ICI recipients, depending on the treatment regimen used. These toxicities vary in severity from mild, asymptomatic cases of subclinical hypothyroidism to severe, fatal cases of adrenal crisis, thyroid dysfunction, or diabetic ketoacidosis. Thus, timely recognition and treatment is critical. Herein, we present clinical cases of ICI-induced thyroid dysfunction, hypophysitis, and insulin-dependent diabetes mellitus. We use these cases to discuss the screening, diagnosis, and management of ICI-associated endocrine dysfunction.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wright JJ, Johnson DB. Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction. J Clin Endocrinol Metab. 2023. PMID: 36481794. doi:10.1210/clinem/dgac689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。